arrow
B

Bob Löwenberg

erasmus university medical center cancer institute
H指数:121
被引数:7.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improved multistate survival in younger AML patients over time

年轻AML患者随时间推移的多状态生存改善

2026-11-030
OAAI
MDS/AML AND AML WITH MYELODYSPLASIA-RELATED GENE MUTATIONS: CLINICAL AND MOLECULAR SIMILARITIES

MDS/AML和AML伴骨髓增生异常相关基因突变: 临床和分子相似性

2026-01-160
OAAI
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

流式细胞术基线可测残留病评估中定量下限作为低水平截断值的预后相关性研究

Leukemia
IF13.4
2025-12-100
OA
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients

高强度治疗患者中急性髓系白血病干细胞定量测定的不同特征。Haematologica

2025-12-012
OA
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中的计算性微小残留病评估:一项在HOVON-SAKK-132试验中的回顾性验证

Leukemia
IF13.4
2025-09-030
OAAI
A revised prognostic model for patients with acute myeloid leukemia and first relapse

针对急性髓系白血病首次复发的修订型预后模型

2025-05-260
OA
Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all-trans retinoic acid

急性早幼粒细胞白血病的早期死亡和颅内出血预测: 在接受化疗加全反式维甲酸治疗的国际联盟队列中验证风险评分

2024-10-310
OAAI
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
2024-10-050
OAAI
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
2024-08-192
OAAI
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study

首次完全缓解的老年急性髓性白血病患者的造血细胞移植: 一项随机III期研究的结果

2024-08-081
OAAI
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
2023-06-193
OAAI
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

中等风险急性髓系白血病患者中可测量的残留疾病引导治疗是减少异基因移植而不影响生存的有价值的策略

2023-04-0612
OAAI